CAR-T with, without mRNA vaccine shows promise for solid tumors

Early data from a phase 1 trial showed encouraging clinical activity for an investigational chimeric antigen receptor T-cell therapy alone or in combination with an amplifying mRNA vaccine for patients with solid tumors.
Forty-three percent of patients treated during the study achieved an objective response, according to results presented at American Association for Cancer Research Annual Meeting.
The investigational treatments used in the trial included BNT211 (BioNTech) — an autologous CAR-T cell therapy that targets the oncofetal antigen Claudin-6 (CLDN6) — and CARVac (BioNTech),

Early data from a phase 1 trial showed encouraging clinical activity for an investigational chimeric antigen receptor T-cell therapy alone or in combination with an amplifying mRNA vaccine for patients with solid tumors.
Forty-three percent of patients treated during the study achieved an objective response, according to results presented at American Association for Cancer Research Annual Meeting.
The investigational treatments used in the trial included BNT211 (BioNTech) — an autologous CAR-T cell therapy that targets the oncofetal antigen Claudin-6 (CLDN6) — and CARVac (BioNTech),